Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events mmong statin-treated patients: a meta-analysis

S. Matthijs Boekholdt, Benoit J. Arsenault, G. Kees Hovingh, Samia Mora, Terje R. Pedersen, John C. LaRosa, K.M.A. Welch, Pierre Amarenco, David A. DeMicco, Andrew M. Tonkin, David R. Sullivan, Adrienne Kirby, Helen M. Colhoun, Graham A. Hitman, D. John Betteridge, Paul N. Durrington, Michael B. Clearfield, John R. Downs, Antonio M. Gotto, Paul M. RidkerJohn J.P. Kastelein

    Research output: Contribution to journalArticlepeer-review

    121 Citations (Scopus)

    Abstract

    It is unclear whether levels of high-density lipoprotein cholesterol (HDL-C) or apolipoprotein A-I (apoA-I) remain inversely associated with cardiovascular risk among patients who achieve very low levels of low-density lipoprotein cholesterol on statin therapy. It is also unknown whether a rise in HDL-C or apoA-I after initiation of statin therapy is associated with a reduced cardiovascular risk.
    Original languageEnglish
    Pages (from-to)1504-1512
    Number of pages9
    JournalCirculation
    Volume128
    Issue number14
    Early online date21 Aug 2013
    DOIs
    Publication statusPublished - 1 Oct 2013

    Fingerprint Dive into the research topics of 'Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events mmong statin-treated patients: a meta-analysis'. Together they form a unique fingerprint.

    Cite this